Clinical Trial Update: S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis [Phase 2]

View source ↗

Summary

Phase 2 trial update on high-dose melphalan with autologous stem cell transplantation for multiple myeloma and primary systemic amyloidosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Myeloma

Drugs mentioned

• high-dose melphalan with autologous peripheral stem cell transplantation

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Multiple Myeloma, Plasma Cell Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2017-11-06